The new crown vaccine is getting closer, and who's going to pay for 1.4 billion people's vaccinations?

(2020/10/15) Xinda hired Liu Yongjun as group president Junshi core technical personnel Wu Hai left, the development of "blue economy": China's marine biopharmaceutical industry development status quo analysis and research, the introduction of anti-monopoly guidance on raw materials can curb monopoly behavior ... (Click on the title, can obtain the original text) "Pharmaceutical 1st time" Xinda hired Liu Yongjun as group president Junshi core technical staff Wu Shi core technical personnel Wu Hai left Xinda Bio today announced the appointment of biopharmaceutical industry famous scientist Dr. Liu Yongjun as the group president.
joining Xinda Bio, Liu Yongjun will be responsible for the Group's global research and development, pipeline strategy, business cooperation and international business, and report to the Group's founder, Chairman and Chief Executive Officer, Yu Dechao.
addition, another domestic innovative pharmaceutical company recently announced personnel changes.
October 13th, Junshi Bio announced that Mr. HAIWU (Wu Hai), the company's director, deputy general manager and core technical staff, had applied to resign as deputy general manager of the company on the same day for personal reasons.
: Recent personnel changes are frequent.
the introduction of anti-monopoly guidance on raw materials and drugs from the "E drug manager" can curb monopoly behavior? On October 13th, the State Administration of Market Supervision issued the Anti-monopoly Guidelines (Draft for Comments) on THE FIELD (hereinafter referred to as the Guidelines) for public consultation.
to prevent and stop monopoly behavior in the field of API, and guide operators in the field of API to operate in compliance with the law.
industry has different voices about the value of this guidance.
: Can severe punishment solve the underlying problem? Eight o'clock: The new crown vaccine is getting closer Who will pay for the vaccination of 1.4 billion people? With more than 40 million new confirmed cases and more than 1 million deaths, the world is waiting for a vaccine.
the threat of this global epidemic is so great that companies have to go through a normal two- to three-year cycle of vaccine development.
optimistic estimate that more than one vaccine will be licensed this year.
But the question is, with 7 billion people worldwide and 1.4 billion people across China barely resistant to the new virus, who will pay for the production, transportation and vaccination of the day's vaccines to defend themselves against deadly threats? Headline: GAVI's step-by-step pricing strategy is a realistic and possible option.
Arterial Network: The development of "blue economy": China's marine biopharmaceutical industry development analysis and research in recent years, many countries will be marine biopharmaceuticals to the strategic development level, the United States, Britain, Spain and other countries have formulated marine biopharmaceutical industry development plans, increase research and development investment in the field of marine biomedicine, as a "blue economy" growth point to promote.
In contrast, although China's marine strategic emerging industries started late, but since 1978, the National Science and Technology Congress put forward "the development of marine lake and marsh resources, the creation of China's blue pharmaceutical industry" and other strategic ideas, 42 years is also accelerating the cultivation and development of marine biopharmaceutical industry.
: Three of the world's 15 marine drugs were born in China.
.